The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia," published in the March 2025 issue of the Molecular Cancer by ...

AbbVie says that navitoclax is a first-in-class therapy, targeting a different part of the BCL-2 pathway to Roche-partnered Venclexta (venetoclax), which is approved to treat chronic lymphocytic ...

Caenorhabditis elegans drp-1 and fis-2 Regulate Distinct Cell-Death Execution Pathways Downstream of ced-3 and Independent ... drp-1 and fis-2 function independent of one another and the Bcl-2 homolog ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

how this is deregulated in diseases such as cancers and exploiting our knowledge of the BCL-2-regulated pathway for developing better therapeutics,” he says. Complementing this research in ...

such as BCL-2, TNF, NF-κB and p53. This interest in part stems from the substantial potential to therapeutically intervene in these pathways, as highlighted in this issue. However, despite ...

it is of utmost importance to conduct research on the molecular pathways underlying the progression ... and change in the mRNA levels of BCL-2/Bax, PTEN, and CDK4 as a consequence of MYC ...

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment ... suggest enhanced activation of stress signaling pathways. These molecular readouts were ...